Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer-Reference-Cited by-同舟云学术

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Published:2020-01-06 Issue:2 Volume:111 Page:561-570
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Takeuchi Shinji¹²,Hase Tetsunari³,Shimizu Shinobu⁴,Ando Masahiko⁴,Hata Akito⁵⁶,Murakami Haruyasu⁷^ORCID,Kawakami Takahiro⁸,Nagase Katsuhiko⁸,Yoshimura Kenichi⁸⁹,Fujiwara Tadami⁴¹⁰,Tanimoto Azusa¹,Nishiyama Akihiro¹,Arai Sachiko¹,Fukuda Koji¹²^ORCID,Katakami Nobuyuki⁵¹¹,Takahashi Toshiaki⁷,Hasegawa Yoshinori³¹²,Ko Tun Kiat¹³,Ong S. Tiong¹³¹⁴¹⁵¹⁶,Yano Seiji¹²^ORCID

Affiliation:

1. Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan

2. Nano Life Science Institute Kanazawa University Kanazawa Japan

3. Department of Respiratory Medicine Nagoya University Graduate School of Medicine Nagoya Japan

4. Department of Advanced Medicine Nagoya University Hospital Nagoya Japan

5. Division of Integrated Oncology Institute of Biomedical Research and Innovation Kobe Japan

6. Department of Medical Oncology Kobe Minimally Invasive Cancer Center Kobe Japan

7. Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

8. Innovative Clinical Research Center (iCREK) Kanazawa University Hospital Kanazawa Japan

9. Department of Data Science Center for Integrated Medical Research Hiroshima University Hospital Hiroshima Japan

10. Clinical Research Center Chiba University Hospital Chiba Japan

11. Department of Medical Oncology Takarazuka City Hospital Takarazuka Japan

12. National Hospital Organization Nagoya Medical Center Nagoya Japan

13. Cancer and Stem Cell Biology Signature Research Program Duke‐NUS Medical School Singapore

14. Department of Haematology Singapore General Hospital Singapore

15. Department of Medical Oncology National Cancer Centre Singapore Singapore

16. Department of Medicine Duke University Medical Center Durham North Carolina USA

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14260

Reference34 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

4. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

5. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

2. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods;Pharmaceuticals;2024-05-10

3. Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer;Journal of Respiration;2023-12-13

4. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects;European Journal of Medicinal Chemistry;2023-12

5. Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective;Cancers;2023-11-13